Revolution Medicines’ Sandler sells 6,309 shares

The option award vests over four years from September 29, 2025, subject to continued service through each vesting date.

Rhea-AI Filing Summary

Revolution Medicines, Inc. Chief Development Officer Alan B. Sandler exercised options for 6,000 shares on September 29, 2026, at an exercise price of $58.84 per share, acquiring 6,000 common shares. His reported option position after the exercise covered 161,300 shares.

That day, Sandler also sold 6,309 shares in five transactions: 2,200 at a weighted average of $200.8188, 1,609 at $201.7239, 1,000 at $202.8127, 1,199 at $203.9074, and 301 at $204.7224 per share. All reported transactions were made pursuant to a Rule 10b5-1 trading plan adopted June 30, 2026.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 7 txns

Insider Sandler Alan B.

Role Chief Development Officer

Sold 6,309 shs ($1.28M)

Approx. gross sale proceeds $1.28M

Approx. exercise cost $353K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F1, F8	6,000	$0.00	$0.00
Exercise	Common Stock F1	6,000	$58.84	$353K
Sale	Common Stock F1, F2	2,200	$200.8188	$442K
Sale	Common Stock F1, F3	1,609	$201.7239	$325K
Sale	Common Stock F1, F4	1,000	$202.8127	$203K
Sale	Common Stock F1, F5	1,199	$203.9074	$244K
Sale	Common Stock F1, F6, F7	301	$204.7224	$62K

Holdings After Transaction: Stock Option (Right to Buy) — 161,300 contracts (Direct); Common Stock — 52,559 shares (Direct)

Footnotes (8)

1. F1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026.
2. F2. The transaction was executed in multiple trades at prices ranging from $200.41 to $201.38, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
3. F3. The transaction was executed in multiple trades at prices ranging from $201.41 to $202.16, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
4. F4. The transaction was executed in multiple trades at prices ranging from $202.42 to $203.34, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
5. F5. The transaction was executed in multiple trades at prices ranging from $203.42 to $204.29, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
6. F6. The transaction was executed in multiple trades at prices ranging from $204.43 to $204.83, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
7. F7. Includes 52,350 restricted stock units.
8. F8. Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from September 29, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Key Figures

Options exercised: 6,000 shares Exercise price: $58.84 per share Common shares acquired through exercise: 6,000 shares +3 more

6 metrics

Options exercised 6,000 shares September 29, 2026

Exercise price $58.84 per share Options exercised September 29, 2026

Common shares acquired through exercise 6,000 shares September 29, 2026

Option position after exercise 161,300 shares Reported after the September 29, 2026 exercise

Shares sold 6,309 shares Five transactions on September 29, 2026

Sale quantities and weighted average prices 2,200 shares at $200.8188; 1,609 at $201.7239; 1,000 at $202.8127; 1,199 at $203.9074; 301 at $204.7224 per share September 29, 2026

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, restricted stock units, Vesting Commencement Date

4 terms

Rule 10b5-1 trading plan regulatory

"made pursuant to a 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"reflects the weighted average sale price"

restricted stock units financial

"Includes 52,350 restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Vesting Commencement Date technical

"measured from September 29, 2025 (the Vesting Commencement Date)"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What trade-price ranges accompanied Alan B. Sandler’s RVMD sales?

The reported ranges were $200.41 to $201.38 for 2,200 shares, $201.41 to $202.16 for 1,609 shares, $202.42 to $203.34 for 1,000 shares, $203.42 to $204.29 for 1,199 shares, and $204.43 to $204.83 for 301 shares.

How did Alan B. Sandler’s RVMD options vest?

Twenty-five percent of the shares subject to the option vest on the first anniversary of September 29, 2025, then one forty-eighth vests on each monthly anniversary. The option is fully vested and exercisable on the fourth anniversary, subject to continued service through each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/01/2026 - 06:00 PM Accepted by SEC EDGAR 10/01/2026 - 06:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sandler Alan B.

(Last) (First) (Middle)

REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/29/2026		M(1)		6,000	A	$58.84	58,868	D
Common Stock	09/29/2026		S(1)		2,200	D	$200.8188(2)	56,668	D
Common Stock	09/29/2026		S(1)		1,609	D	$201.7239(3)	55,059	D
Common Stock	09/29/2026		S(1)		1,000	D	$202.8127(4)	54,059	D
Common Stock	09/29/2026		S(1)		1,199	D	$203.9074(5)	52,860	D
Common Stock	09/29/2026		S(1)		301	D	$204.7224(6)	52,559(7)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$58.84	09/29/2026		M(1)			6,000	(8)	11/01/2035	Common Stock	167,300	$0	161,300	D

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026.

2. The transaction was executed in multiple trades at prices ranging from $200.41 to $201.38, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

3. The transaction was executed in multiple trades at prices ranging from $201.41 to $202.16, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

4. The transaction was executed in multiple trades at prices ranging from $202.42 to $203.34, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

5. The transaction was executed in multiple trades at prices ranging from $203.42 to $204.29, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

6. The transaction was executed in multiple trades at prices ranging from $204.43 to $204.83, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

7. Includes 52,350 restricted stock units.

8. Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from September 29, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

	/s/ Jack Anders, as Attorney-in-fact for Alan B. Sandler	10/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)